Patents Represented by Attorney, Agent or Law Firm Anna L. Cocuzzo
  • Patent number: 6531314
    Abstract: Human, swine and rat growth hormone secretagogue receptors have been isolated, cloned and sequenced. Growth hormone secretagogue receptors are new members of the G-protein family of receptors. The growth hormone secretagogue receptors may be used to screen and identify compounds which bind to the growth hormone secretagogue receptor. Such compounds may be used in the treatment of conditions which occur when there is a shortage of growth hormone, such as observed in growth hormone deficient children, elderly patients with musculoskeletal impairment and recovering from hip fracture and osteoporosis.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: March 11, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Joseph P. Arena, Doris F. Cully, Scott D. Feighner, Andrew D. Howard, Paul A. Liberator, James M. Schaeffer, Leonardus H. T. Van Der Ploeg
  • Patent number: 6521426
    Abstract: Adenoviral particles are produced by incubating cells containing a helper adenovirus vector and a helper-dependent adenoviral vector including an Adeno-Associated Virus (AAV) rep gene, such as rep 78. Cells are provided containing a helper adenovirus vector. A helper-dependent adenoviral vector including an AAV rep gene is introduced into the cells, for instance by infection with infective viral particles. The cells are incubated to produce adenoviral particles containing nucleic acid including the AAV rep gene. Advantageously, cells containing helper adenovirus vector are pre-incubated for 0.5-12 hours, preferably about 4 hours, to allow expression of viral proteins required for adenoviral genome replication before introducing the helper-dependent adenovirus vector including an AAV rep gene.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: February 18, 2003
    Assignee: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Gennaro Ciliberto, Stefano Colloca, Nicola La Monica
  • Patent number: 6475755
    Abstract: The subject matter of the present invention are recombinant defective adenoviruses comprising a heterologous DNA sequence coding for a mutein having the activity of human Interleukin 6 (hIL-6) antagonists or superantagonist. Moreover, the invention refers to therapeutical uses thereof, in particular for preparing pharmaceutical compositions for treating and/or preventing pathologies caused by hIL-6 overproduction.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: November 5, 2002
    Assignees: Instituto di Ricerche di Biologgia Molecolare, Centre National de la Recherche Scientifique
    Inventors: Gennaro Ciliberto, Isabella Saggio, Rocco Savino, Michel Perricaudet
  • Patent number: 6372425
    Abstract: A process of purifying target molecules is described that involves the selection of ligands based on identifying, in real time, association and dissociation constants with a given target molecule; using this information to select at least one ligand that exhibit predetermined association and dissociation constants with a given target molecule; anchoring a quantity of ligand to an activated solid support; contacting a quantity of target molecules with the anchored ligand(s); removing low affinity target molecules from anchored ligand and eluting particularly pure target molecules.
    Type: Grant
    Filed: August 21, 1998
    Date of Patent: April 16, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Beth Arnold, Paul M. Keller, Anthony J. Conley, Alan R. Shaw, Jwu-Sheng Tung
  • Patent number: 6300476
    Abstract: Anti-peptide antibody raised against a portion of human cytochrome P450 3A4 is disclosed. A particular anti-peptide antibody was raised against a 21-amino acid peptide corresponding to residues 253-273 of human cytochrome P450 3A4. High titer antibodies were produced by rabbits immunized with this peptide as judged by ELISA. This anti-peptide antibody is specific for human CYP3A4 and exhibited greater than 90-95% inhibition of testosterone 6&bgr;-hydroxylation, while other cytochrome P450-mediated reactions in human liver microsomes were not inhibited. An inhibitory epitope has been mapped within amino acids 261-267 of human CYP3A4.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: October 9, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Anthony Y. H. Lu, Regina W. Wang
  • Patent number: 6281346
    Abstract: The rat ob receptor gene has been isolated and cloned. Two different alleles have been identified: the wild-type, and the fa-allele which differs from the wild type by only one base pair. The base pair change, however introduces an MspI restriction site into the DNA sequence, and also results in an amino acid change. Also part of the invention are the receptors, vectors containing the nucleic acid encoding the receptors, host cells transformed with this gene, and assays which use the gene or protein and identify new ligands.
    Type: Grant
    Filed: February 20, 1997
    Date of Patent: August 28, 2001
    Assignee: Merck & Co., Inc.
    Inventors: John W. Hess, C. Thomas Caskey, Qingyun Liu, Michael Sean Phillips
  • Patent number: 6258944
    Abstract: The ob receptor has numerous isoforms resulting from alternative splicaing; three novel isoforms, designated c′, f, and g are disclosed. The nucleic acids encoding these isoforms are taught. Also part of the invention are vectors containing the nucleic acid encoding the receptors, host cells transformed with these genes, and assays which use the genes or protein isoforms.
    Type: Grant
    Filed: May 6, 1997
    Date of Patent: July 10, 2001
    Assignee: Merck & Co., Inc.
    Inventors: C. Thomas Caskey, Patricia Hey, John W. Hess, Michael Sean Phillips
  • Patent number: 6242199
    Abstract: An assay for the detection of growth hormone secretagogue receptors and growth hormone secretagogue related receptors is described. As these receptors are a member of the G protein coupled receptors, a subunit of the G protein must be present in order for expression to be detected. A similar assay is described where the presence of growth hormone secretagogues are detected.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: June 5, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Lee-Yuh Pai, Scott D. Feighner, Andrew D. Howard, Sheng-Shung Pong, Leonardus H. T. Van Der Ploeg
  • Patent number: 6194210
    Abstract: A microcarrier based process to produce viral vaccines, of which one example is hepatitis A virus (HAV), is composed of an aggregated microcarrier system of glass coated polystyrene microcarriers and MRC-5 cells which creates a stable environment for the propagation of the virus over even extended infection periods. The microcarrier aggregates formed according to this process eliminate the sloughing of cells from the beads during long cultivations seen in other systems, allowing high virus productivity in microcarrier culture. The methodology is applicable where virus production can be enhanced by creating a stable culture during an extended infection period. Scalable stirred bioreactors are used instead of multiple parallel stationary surface bioreactors.
    Type: Grant
    Filed: April 17, 1996
    Date of Patent: February 27, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Frank S. Leu, Douglas B. Seifert
  • Patent number: 6057113
    Abstract: The full-length mouse .beta.3 integrin has been cloned and sequenced. A new form of .beta.3 integrin (.beta.3-trunc also been cloned and sequenced.
    Type: Grant
    Filed: December 22, 1998
    Date of Patent: May 2, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Le T. Duong, Gideon A. Rodan, Elka M. Nutt
  • Patent number: 6007998
    Abstract: A trans-activation assay for leptin is described. Leptin response elements are located proximal to a promoter, and the promoter region is operatively linked to a reporter gene. When leptin binds with the receptor, the reporter gene is transcribed.
    Type: Grant
    Filed: April 21, 1997
    Date of Patent: December 28, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Charles I. Rosenblum, Leonardus H. T. Van Der Ploeg, Sajjad A. Qureshi, Doris F. Cully, John W. Hess, Michael R. Tota, Fang Chen
  • Patent number: 6001816
    Abstract: Gene therapy can treat obesity in mammals. An adenoviral vector encoding a leptin gene is delivered intravenously to a mammal with a deficiency in functional leptin to decrease weight, decrease serum insulin levels or decrease serum glucose levels.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: December 14, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Manal A. Morsy, Ming Cheng Gu, Jing Zhoa, C. Thomas Caskey